United States Patent 7,825,137: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 7,825,137, titled "Method of treating abnormal cell growth," is a significant patent in the field of medical science, particularly in the treatment of cancers. This patent, assigned to Pfizer Inc., involves a method for treating abnormal cell growth using a specific compound that inhibits the c-Met/HGFR pathway. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Overview
Publication and Filing Details
- Publication Number: US7825137B2
- Filing Date: August 14, 2007
- Grant Date: January 4, 2011
- Assignee: Pfizer Inc.[4]
Invention Summary
The patent describes a method for treating abnormal cell growth, particularly in the context of cancer, by using a compound that inhibits the c-Met/HGFR (hepatocyte growth factor receptor) pathway. This pathway is crucial in the regulation of cell growth and is often implicated in the progression of various cancers.
Scope of the Patent
Technical Field
The patent falls under the category of medical or veterinary science, specifically in the area of preparations for medical purposes. The classification includes:
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom[4].
Compound and Mechanism
The patent focuses on a specific compound, referred to as "Compound 1," which has anti-tumor properties. This compound works by inhibiting the c-Met/HGFR pathway, which is involved in the regulation of cell growth and is often dysregulated in cancer cells.
Claims of the Patent
Independent and Dependent Claims
The patent includes several claims that define the scope of the invention:
- Independent Claims: These claims define the broadest scope of the invention, including the method of treating abnormal cell growth using the specified compound.
- Dependent Claims: These claims narrow down the scope by specifying particular aspects of the method, such as the dosage, administration route, and specific types of cancers treated[4].
Key Claim Elements
- The method involves administering a therapeutically effective amount of Compound 1 to a subject in need thereof.
- The compound is described in terms of its chemical structure and its ability to inhibit the c-Met/HGFR pathway.
- The claims also cover various formulations and methods of administration of the compound.
Patent Landscape
Related Patents
The patent landscape surrounding US7825137B2 includes several related patents and applications:
- International Patent Applications: The patent references International Patent Applications No. PCT/IB2005/002837 and No. PCT/IB05/002695, which are incorporated by reference[4].
- U.S. Patent Applications: The patent also references U.S. patent applications Ser. No. 11/212,331 and Ser. No. 11/213,039[4].
Expiration Dates
- The patent is set to expire on May 12, 2027, marking the end of the exclusive rights granted to Pfizer Inc.[5].
Generic Availability
As of the current date, there is no therapeutically equivalent generic version of the drug associated with this patent available in the United States. The patent expiration date will be a critical factor in determining when generic versions can be developed and marketed[5].
Impact on Cancer Treatment
Clinical Significance
The invention described in this patent has significant clinical implications for the treatment of cancers. The c-Met/HGFR pathway is a key target in cancer therapy, and the compound described has shown promise in inhibiting this pathway, thereby reducing abnormal cell growth.
Market and Competitive Landscape
The patent's exclusivity period has allowed Pfizer Inc. to maintain a monopoly on the market for this specific treatment. However, as the patent approaches its expiration date, other pharmaceutical companies may begin to develop generic or biosimilar versions, potentially altering the market dynamics.
Legal and Regulatory Aspects
Patent Infringement
The exclusive rights granted by this patent protect Pfizer Inc. from patent infringement. Any attempts to manufacture, use, or sell the described compound or method without permission would be considered infringement[4].
FDA Exclusivity
In addition to patent protection, the drug may also have FDA exclusivity, which grants the manufacturer sole marketing rights for a specified period. This can run concurrently with the patent term and provides additional protection against generic competition[5].
Conclusion
United States Patent 7,825,137 is a critical patent in the field of cancer treatment, focusing on a method for inhibiting abnormal cell growth using a specific compound. The patent's scope and claims are well-defined, and its expiration date will significantly impact the pharmaceutical market. Understanding the patent landscape and the legal and regulatory aspects surrounding this patent is essential for both pharmaceutical companies and researchers.
Key Takeaways
- Patent Scope: The patent covers a method for treating abnormal cell growth using a compound that inhibits the c-Met/HGFR pathway.
- Claims: The patent includes independent and dependent claims that define the method, compound, and its administration.
- Related Patents: The patent references several international and U.S. patent applications.
- Expiration Date: The patent is set to expire on May 12, 2027.
- Clinical Impact: The invention has significant implications for cancer treatment.
- Market Dynamics: The patent's expiration will affect the market for generic and biosimilar versions.
FAQs
Q: What is the main subject of United States Patent 7,825,137?
A: The main subject is a method for treating abnormal cell growth, particularly in cancer, using a compound that inhibits the c-Met/HGFR pathway.
Q: Who is the assignee of this patent?
A: The assignee is Pfizer Inc.
Q: When is the patent set to expire?
A: The patent is set to expire on May 12, 2027.
Q: What is the significance of the c-Met/HGFR pathway in cancer treatment?
A: The c-Met/HGFR pathway is crucial in the regulation of cell growth and is often implicated in the progression of various cancers.
Q: Are there any generic versions of the drug associated with this patent available?
A: As of the current date, there are no therapeutically equivalent generic versions available in the United States.
Sources
- USPTO - Search for patents: https://www.uspto.gov/patents/search
- U.S. Patent and Trademark Office (USPTO) | USAGov: https://www.usa.gov/agencies/u-s-patent-and-trademark-office
- Patent Claims Research Dataset - USPTO: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
- US7825137B2 - Method of treating abnormal cell growth - Google Patents: https://patents.google.com/patent/US7825137B2/en
- Generic Xalkori Availability - Drugs.com: https://www.drugs.com/availability/generic-xalkori.html
